Zembrace SymTouch and Tosymra offer migraine pain relief onset in 10 minutes. Credit: Usman Yousaf on Unsplash.

Tonix Pharmaceuticals and its subsidiary Tonix Medicines have signed an agreement for the acquisition of Upsher-Smith Laboratories’ two migraine products.

The US Food and Drug Administration (FDA)-approved products, Zembrace SymTouch (sumatriptan injection) 3mg and Tosymra (sumatriptan nasal spray) 10mg, are intended to treat adult patients with acute migraine irrespective of aura status, and offer migraine pain relief onset in just under ten minutes.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Zembrace SymTouch is a sumatriptan autoinjector while Tosymra is a new intranasal sumatriptan product.

These products together generated sales of $23m in 2022.

Upsher-Smith is entitled to receive an upfront payment of $12m in cash from Tonix Medicines on the closure of the deal.

Tonix Medicines will make a payment of $3m in March 2024, or on completing the transition services period.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Upsher-Smith will also receive $10m in cash from Tonix Medicines on taking over specific product-linked inventories.

Tonix Pharmaceuticals CEO Seth Lederman stated: “Sumatriptan remains the acute migraine ‘gold standard’ treatment for many patients and continues to represent the largest segment of the market in terms of unit sales. 

“With migraine pain relief possible in as little as ten minutes for some patients and convenient administration, we believe both Zembrace SymTouch and Tosymra are well-suited to address the unmet needs of patients using traditional or emerging oral acute migraine medications, particularly for rapid-onset treatment.”

In April 2022, Tonix Pharmaceuticals and Kansas State University in the US signed a preclinical research agreement to develop TNX-2300, a live virus vaccine for Covid-19.